XBiotech Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, XBiotech is in Stage 4, the downtrend phase, now in week 16 (since Jul 2, 2026). It closed at $1.97, 33.0% below its 52-week high and below its 200-day average, which is falling.

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. More about the company

$1.97

-1.00% today

$60.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XBIT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 17w

S2 14w

S4 31w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 10w → S4 8w → S1 7w → S2 17w → S3 10w → S4 1w → S3 1w → S2 14w → S3 1w → S4 31w → S1 9w → S4 16w → S1 6w → S4 9w → S1 8w → S4 16w current

Total tracked: 165 weeks across 17 stage runs.

XBIT among Biotechnology258th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…258	XBITXBiotech Inc.	Stage 4 · wk 16	37	−9.6%

vs 52W High

-33.0%

$1.97 lo$2.94 hi

33.0% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-16.0%

200 DMA: $2.34 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.14x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-9.6%

-13.2%

-22.1%

YTD

-17.2%

-23.9%

Scan Membership

Breakout Watch

Latest: 2024-09-06

9 appearances in last 60 days. First seen: 2018-12-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 0.14x

2026-10-21S4

Wk 16 · Vol 1.00x

2026-10-20S4

Wk 16 · Vol 0.79x

2026-10-19S4

Wk 16 · Vol 8.64x

2026-10-16S4

Wk 15 · Vol 1.58x

2026-10-15S4

Wk 15 · Vol 2.01x

2026-10-14S4

Wk 15 · Vol 1.59x

2026-10-13S4

Wk 15 · Vol 1.95x

2026-10-12S4

Wk 15 · Vol 1.04x

2026-10-09S4

Wk 14 · Vol 2.28x

2026-10-08S4

Wk 14 · Vol 0.33x

2026-10-07S4

Wk 14 · Vol 2.69x

Moving averages & range

50 DMA

$2.20

200 DMA

$2.34

52W High

$2.94

52W Low

$1.97

5D Low

$1.97

Resistance levels (recent highs)

20d High

$2.29

60d High

$2.46

120d High

$2.55

250d High

$2.94

Next resistance

+16.2%

to 20d High

ROE

-29.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.5

XBiotech: quick answers

What stage is XBiotech in?

As of Oct 22, 2026, XBiotech (XBIT) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 2, 2026 and is in week 16. What the four stages mean

Is XBiotech in an uptrend?

No. XBiotech is in a Stage 4 downtrend. It trades 16.0% below its 200-day average, which is falling.

How far is XBiotech from its 52-week high?

XBiotech closed at $1.97 on Oct 22, 2026, 33.0% below its 52-week high of $2.94. Its 52-week low is $1.97.

How has XBiotech performed over the past year?

As of Oct 22, 2026, XBiotech is down 23.9% over the past year and down 17.2% so far in 2026.

Which sector and industry is XBiotech in?

XBiotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.